Posverdad del consumo de cannabis: de regreso a la medicina basada en la evidencia
DOI:
https://doi.org/10.20882/adicciones.1095Palabras clave:
Cannabis, Prevención, Investigación, Evaluación, Medicina basada en la evidenciaResumen
La opinión pública y científica sobre los efectos beneficios y perjudiciales del consumo regular de cannabis no está exenta del fenómeno de la posverdad. En esta editorial revisamos la evidencia científica de los efectos perjudiciales del consumo regular de cannabis (salud física, mental, consecuencias sociale, etc.), del uso medicinal del mismo (dolor, epilepsia, VIH, etc.) y de los vacíos en la investigación en este campo. Por último, desarrollamos una recomendación de abordaje de la situación desde un punto de vista de la salud pública y la investigación clínica y preventiva.Citas
Allen, J. H., de Moore, G. M., Heddle, R. y Twartz, J. C. (2004). Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut, 53, 1566–1570. doi:10.1136/gut.2003.036350.
Álvarez, A., Gamella, J. F. y Parra, I. (2016). La legalización de los derivados del cannabis en España: Hipótesis sobre un potencial mercado emergente. Adicciones, 29, 195-206. doi:10.20882/adicciones.807.
Apfel, F. (2013). Cannabis – from prohibition to regulation “When the music changes so does the dance.” Recuperado de http://www.alicerap.eu/.
Baccini, M. y Carreras, G. (2014). Analyzing and Comparing the Association Between Control Policy Measures and Alcohol Consumption in Europe. Substance Use & Misuse, 49, 1684–1691. doi:10.3109/10826084.2014.914373.
Blake, A., Wan, B. A., Malek, L., DeAngelis, C., Diaz, P., Lao, N., … O’Hearn, S. (2017). A selective review of medical cannabis in cancer pain management. Annals of Palliative Medicine, 6, 805–805. doi:10.21037/apm.2017.08.05.
Blasco-Fontecilla, H. (2018). Posmodernidad, sociedades adictivas, cannabis y comportamiento suicida: ¿Hacia un mundo feliz? Adicciones, 30, 3-8. doi:10.20882/adicciones.1104.
Bruguera, P., López-Pelayo, H., Miquel, L. y Balcells-Oliveró, M. (2016). High prevalence of cannabinoid hyperemesis syndrome in marijuana users. Emergencias, 28, 249-251.
Carney, T., Myers, B. J., Louw, J. y Okwundu, C. I. (2016). Brief school-based interventions and behavioural outcomes for substance-using adolescents. In T. Carney (Ed.), Cochrane Database of Systematic Reviews (p. CD008969). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD008969.pub3.
Casajuana, C., López-Pelayo, H., Balcells, M. M., Colom, J. y Gual, A. (2017). Constituyentes psicoactivos del cannabis y sus implicaciones clínicas: una revisión sistemática. Adicciones. Avance de publicación on-line. doi:10.20882/adicciones.858.
Casajuana, C., López-Pelayo, H., Mercedes Balcells, M., Miquel, L., Teixidó, L., Colom, J. y Gual, A. (2017). Estableciendo la unidad de porro estándar: estudio piloto. Adicciones, 29, 227-232. doi:10.20882/adicciones.721.
Casajuana Kögel, C., Balcells-Olivero, M. M., López-Pelayo, H., Miquel, L., Teixidó, L., Colom, J., … Gual, A. (2017). The Standard Joint Unit. Drug and Alcohol Dependence, 176, 109–116. doi:10.1016/j.drugalcdep.2017.03.010.
Sánchez Caballero, D. (2014). Cada vez más jóvenes españoles apoyan la legalización del cannabis. Eldiario.es. Recuperado de http://www.eldiario.es/sociedad/Quemando-etapas-regulacion-cannabis_0_296070879.html.
Delegación del Gobierno para Plan Nacional sobre Drogas. (2015). Encuesta sobre alcohol y drogas en población general España EDADES 2015-2016.
Denis, C., Lavie, E., Fatseas, M. y Auriacombe, M. (2006). Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. In C. Denis (Ed.), Cochrane Database of Systematic Reviews (p. CD005336). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD005336.pub2.
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., … Room, R. (2017). Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 107, 1277–1277. doi:10.2105/AJPH.2017.303818a.
Flood, A. (2016). Post-truth’ named word of the year by Oxford Dictionaries. The Guardian. Recuperado de https://www.theguardian.com/books/2016/nov/15/post-truth-named-word-of-the-year-by-oxford-dictionaries.
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B. y Gowing, L. (2016a). Psychosocial interventions for cannabis use disorder. In P. J. Gates (Ed.), Cochrane Database of Systematic Reviews (p. CD005336). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD005336.pub4.
Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B. y Gowing, L. (2016b). Psychosocial interventions for cannabis use disorder. The Cochrane Database of Systematic Reviews, (5), CD005336. doi:10.1002/14651858.CD005336.pub4.
Gloss, D. y Vickrey, B. (2014). Cannabinoids for epilepsy. In D. Gloss (Ed.), Cochrane Database of Systematic Reviews (p. CD009270). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD009270.pub3.
Goldenberg, M., Reid, M. W., IsHak, W. W. y Danovitch, I. (2017). The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. Drug and Alcohol Dependence, 174, 80–90. doi:10.1016/j.drugalcdep.2016.12.030.
Gual, A., Segura, L., Contel, M., Heather, N. y Colom, J. (2002). AUDIT-3 and AUDIT-4: effectiveness of two short forms of the Alcohol Use Disoders Identification Test. Alcohol and Alcoholism, 37, 591–596.
Gurney, S. M. R., Scott, K. S., Kacinko, S. L., Presley, B. C. y Logan, B. K. (2014). Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Science Review, 26, 54–76.
Hall, W. (2014). What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction, 110, 19-35. doi:10.1111/add.12703.
Hall, W. (2017). Alcohol and cannabis: Comparing their adverse health effects and regulatory regimes. The International Journal on Drug Policy, 42, 57–62. doi:10.1016/j.drugpo.2016.10.021.
Hill, A. B. (1965). The environment and disease: association or causation? Proceedings of the Royal Society of Medicine, 58, 295–300.
Krishnan, S., Cairns, R. y Howard, R. (2009). Cannabinoids for the treatment of dementia. In S. Krishnan (Ed.), Cochrane Database of Systematic Reviews (p. CD007204). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD007204.pub2.
Lachenmeier, D. W. y Rehm, J. (2015). Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Scientific Reports, 5, 8126. doi:10.1038/srep08126.
Lutge, E. E., Gray, A. y Siegfried, N. (2013). The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. In E. E. Lutge (Ed.), Cochrane Database of Systematic Reviews (p. CD005175). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD005175.pub3.
Lynskey, M. y Hall, W. (2000). The effects of adolescent cannabis use on educational attainment: a review. Addiction (Abingdon, England), 95, 1621–1630.
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M. y Vassos, E. (2016). Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophrenia Bulletin, 42, 1262–1269. doi:10.1093/schbul/sbw003.
Marshall, K., Gowing, L., Ali, R. y Le Foll, B. (2014). Pharmacotherapies for cannabis dependence. In L. Gowing (Ed.), Cochrane Database of Systematic Reviews (p. CD008940). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD008940.pub2.
Matrai, S., Casajuana, C., Allamani, A., Baccini, M., Pepe, P., Massini, G. y Gual, A. (2014). The relationships between the impact of alcoholic beverage control policies, selected contextual determinants, and alcohol drinking in Spain. Substance Use & Misuse, 49(12), 1665–1683. doi:10.3109/10826084.2014.913398.
Mounteney, J., Griffiths, P., Sedefov, R., Noor, A., Vicente, J. y Simon, R. (2016). The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction, 111, 34–48. doi.org/10.1111/add.13056.
Murray, R. M., Quigley, H., Quattrone, D., Englund, A. y Di Forti, M. (2016). Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry, 15, 195–204. doi:10.1002/wps.20341.
Oxford English Living Dictionaries. (2017). Recuperado de
https://en.oxforddictionaries.com/definition/post-truth.
Pélissier, F., Claudet, I., Gandia-Mailly, P., Benyamina, A. y Franchitto, N. (2016). Cannabis Hyperemesis Syndrome in the Emergency Department: How Can a Specialized Addiction Team Be Useful? A Pilot Study. The Journal of Emergency Medicine, 51, 544–551. doi:10.1016/j.jemermed.2016.06.009.
Phillips, R. S., Friend, A. J., Gibson, F., Houghton, E., Gopaul, S., Craig, J. V y Pizer, B. (2016). Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. In R. S. Phillips (Ed.), Cochrane Database of Systematic Reviews (Vol. 2, p. CD007786). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD007786.pub3.
Richards, B. L., Whittle, S. L. y Buchbinder, R. (2012). Neuromodulators for pain management in rheumatoid arthritis. In B. L. Richards (Ed.), Cochrane Database of Systematic Reviews (Vol. 1, p. CD008921). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD008921.pub2.
Schuermeyer, J., Salomonsen-Sautel, S., Price, R. K., Balan, S., Thurstone, C., Min, S.-J. y Sakai, J. T. (2014). Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11. Drug and Alcohol Dependence, 140, 145–155. doi:10.1016/j.drugalcdep.2014.04.016.
Simonetto, D. A., Oxentenko, A. S., Herman, M. L. y Szostek, J. H. (2012). Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clinic Proceedings, 87, 114–119. doi:10.1016/j.mayocp.2011.10.005.
Smith, L. A., Azariah, F., Lavender, V. T., Stoner, N. S. y Bettiol, S. (2015). Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. In L. A. Smith (Ed.), Cochrane Database of Systematic Reviews (p. CD009464). Chichester, UK: John Wiley & Sons, Ltd. doi:10.1002/14651858.CD009464.pub2.
Sobesky, M. y Gorgens, K. (2016). Cannabis and adolescents: Exploring the substance misuse treatment provider experience in a climate of legalization. International Journal of Drug Policy, 33, 66–74. doi:10.1016/j.drugpo.2016.02.008.
Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T. y Monte, A. A. (2017). Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment—a Systematic Review. Journal of Medical Toxicology, 13, 71–87. doi:10.1007/s13181-016-0595-z.
Taylor, L. E., Swerdfeger, A. L. y Eslick, G. D. (2014). Vaccines are not associated with autism: An evidence-based meta-analysis of case-control and cohort studies. Vaccine, 32, 3623–3629. doi:10.1016/j.vaccine.2014.04.085.
Tomeny, T. S., Vargo, C. J. y El-Toukhy, S. (2017). Geographic and demographic correlates of autism-related anti-vaccine beliefs on Twitter, 2009-15. Social Science & Medicine, 191, 168–175. doi:10.1016/j.socscimed.2017.08.041.
Tournebize, J., Gibaja, V. y Kahn, J.-P. (2017). Acute effects of synthetic cannabinoids: Update 2015. Substance Abuse, 38, 344–366. doi:10.1080/08897077.2016.1219438.
Walitt, B., Klose, P., Fitzcharles, M.-A., Phillips, T. y Häuser, W. (2016). Cannabinoids for fibromyalgia. The Cochrane Database of Systematic Reviews, 7, CD011694. doi:10.1002/14651858.CD011694.pub2.
Wang, G. S., Le Lait, M.-C., Deakyne, S. J., Bronstein, A. C., Bajaj, L. y Roosevelt, G. (2016). Unintentional Pediatric Exposures to Marijuana in Colorado, 2009-2015. JAMA Pediatrics, 170, e160971. doi:10.1001/jamapediatrics.2016.0971.
Washington, D. T. N. A. P. (Ed.). (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. doi:10.17226/24625.
World Health Organization. (2017). Management of substance abuse. Recuperado de http://www.who.int/substance_abuse/terminology/definition3/en/